Structural Features, Biological Functions of the Alpha-1 Antitrypsin and Contribution to Esophageal Cancer by Shahla Mohammad Ganji et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Structural Features, Biological  
Functions of the Alpha-1 Antitrypsin and 
Contribution to Esophageal Cancer 
Shahla Mohammad Ganji1, 
Ferdous Rastgar Jazii1 and Abbas Sahebghadam-Lotfi1,2 
1Department of Biochemistry, National Institute of Genetic  
Engineering and Biotechnology (NIGEB), Tehran 
2Department of Biochemistry, Tarbiat Modares University, Tehran 
Iran 
1. Introduction 
Alpha-1 antitrypsin (AAT) is a member of the serine protease inhibitors (serpin) family. 
Hepatocytes are the major source of synthesis and secretion of AAT into the blood stream, 
however macrophages of the lungs also take part in this process to a lower extent [1]. AAT is 
a proteolytic enzyme which plays major role in the normal physiological processes such as 
angiogenesis, intravascular fibrinolyis, and wound healing. However it may also participate 
in pathological conditions such as tumor invasion and metastasis which require degradation 
of the basement membrane, stimulation of angiogenesis, and migration [2, 3]. 
Following to synthesis AAT diffuses into tissues where it targets neutrophil elastase, a 
powerful protease capable of cleaving elastic fibers of alveolar walls and other structural 
proteins [4]. Apart from synthesis in the liver, AAT may also be synthesized and secreted by 
the epithelial cells of stomach, intestine, pancreas, and respiratory tract. Additionally, it can 
be produced by certain cancer cells, including cancers of gastric, colon, and lung. Tumor 
cells synthesize and release not only an intact native form of AAT, but also a variety of 
cleaved and/or degraded forms of alpha-1 antitrypsin. AAT has multiple effects on tumor 
cell viability and play diverse roles in tumorigenesis [2].  
Being the most abundant human serum protease inhibitor, AAT is encoded by a single gene of 
12.2 kb in length, which is located on the long arm of chromosome 14 (14q31-32.2). The protein 
is highly polymorphic and a number of alleles have so far been identified for it. These alleles 
are classified into the following four groups; group 1 or normal allele, whose product is AAT 
with normal function and serum level ranging from 150 up to 350 mg/dL -1. Group 2 or the 
deficient alleles is associated with serum AAT level less than 35% of normal subjects. In 
addition group 2 alleles may also not function normally. Group 3 includes the null allele as 
this group display no detectable serum AAT; and finally group 4 which includes dysfunctional 
alleles. The last group encodes AAT present at normal level; however, the AAT produced by 
this group is a non-functional AAT [5, 6]. Mutations in the AAT gene has shown to be 
associated with a number of diseases including Cirrhosis, COPD, pneumothorax, asthma, 
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wegener's granulomatosis, pancreatitis , gallstones, bronchiectasis, pelvic organ prolapse, 
primary sclerosing cholangitis, autoimmune hepatitis, emphysema (predominantly involving 
the lower lobes and causing bullae), renal, and arthritis. In addition in other malignancies such 
as Hepatocellular carcinoma, Bladder carcinoma, Gallbladder cancer, Lymphoma, and lung 
cancer defects and mutations of AAT have also been reported [7, 8]. 
2. Alpha-1 antitrypsin deficiency (AATD), conformational disease 
Alpha-1 antitrypsin deficiency (AATD) is an autosomal recessive genetic disorder caused by 
defective production of AAT, which leads to the decreased AAT activity in blood and lungs, 
and deposition of excessive abnormal AAT protein in liver cells. Severe AAT deficiency 
causes panacinar emphysema or COPD in adults with complications, especially if they were 
exposed to cigarette smoke. It also include subjects with various liver diseases in a minority 
of children and adults [9].  
Symptoms of AATD include short dyspnea, wheezing, rhonchi, and rales (Crackles). The 
patient's symptoms may resemble recurrent respiratory infections or asthma that doesn’t 
respond to treatment. Individuals with AATD may develop emphysema during their 
thirties or forties even without a history of significant smoking, though smoking greatly 
increases the risk for emphysema. AATD also causes impaired liver function in some 
patients and may lead to cirrhosis and liver failure (15%). It is a leading cause of liver 
transplantation in newborns. 
The conformational diseases [10], which include diverse disorders such as Alzheimer’s and 
Parkinson’s, amyloidoses, AAT deficiency and the prion encephalopathies, take place due to 
conformational rearrangements of a specific protein that endows a tendency to aggregate 
formation and deposition within tissues or cellular compartments [11]. AAT deficiency 
serves as an excellent model for conformational disease because it is one of the few members 
of this class for which detailed structural data are available on both the wild type and 
mutant proteins [11]. Indeed, familial conformational diseases occur when a mutation alters 
specific conformation of protein resulting in abnormal intermolecular interactions, protein 
aggregation, and consequent tissue damage. The molecular mechanisms of conformational 
disease are best understood for the serine protease inhibitor (serpin) superfamily of 
proteins. The serpinopathies include alpha-1 antitrypsin (SERPINA1) deficiency and the 
newly characterized familial encephalopathy with neuroserpin inclusion bodies (FENIB) 
resulting from mutations in the neuroserpin (SERPINI1) gene [12]. 
Robin Carrell and Lomas [11] have described structural rearrangements that take place 
when AAT meets and inactivates its target, the serine proteases. In the case of AAT, this 
inherent instability allows the proteins to undergo loop-sheet polymerization, creating an 
abnormal structure in which the loop from the active site of one AAT molecule inserts itself 
as another -strand into a pre-existing -sheet of an adjacent molecule [11], [13, 14]. In the 
figure 1, the mechanism of inhibition of proteases by serpins and mutations resulting in 
disease has been shown [14]. This intrinsic tendency of wild-type AAT to undergo structural 
transformation is markedly enhanced in mutant forms. As such forms are more prone to 
accommodate the extraneous strand from an adjacent molecule since mutations destabilize 
the sheet, allowing an increased mobility of its constituent strands. This loop–sheet  
insertion is an example of conversion of a loop to a beta- strand through interactions  
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Fig. 1. Mechanism of inhibition of proteases by serpins and mutations resulting in disease. 
The mechanism of inhibition of the serpins, represented in Panel A by AAT, is like that of a 
mousetrap, with a springlike shift from a metastable to a hyperstable state. The protease 
attacks the reactive center loop (yellow) of alpha1-antitrypsin, with the active serine of the 
protease (small red side chain) forming a link to the amino acid at the base of the reactive 
center (small green side chain) of alpha 1-antitrypsin. The resulting cleavage of the reactive 
loop allows it to snap back into the main b sheet (red ribbons with arrows) of the alpha 1 -
antitrypsin. This spring-like movement flings the tethered protease to the opposite end of 
the alpha1 -antitrypsin molecule, distorting its active site (inset) and altering its structure so 
that it can be destroyed. 
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A sum 200 different mutations in serpins are known to result in disease (Panel B). In 
particular, mutations affecting antithrombin confer a predisposition to thrombosis, those 
affecting C1 inhibitor confer a predisposition to angioedema, and those affecting 
antiplasmin confer a predisposition to hemorrhage. Mutations at the reactive center result in 
a loss of function (e.g., causing familial angioedema) or more rarely result in a change in 
function (e.g., causing hemorrhagic disease). The insertion of an amino acid into the peptide 
loop containing the reactive center of another serpin, alpha2-antiplasmin, reduces the 
distortion of the catalytic site (inset) of plasmin, allowing its release, with consequent 
fibrinolysis and hemorrhage. The most common cause of loss of function of serpin 
molecules are mutations affecting the critical mobile hinges of the molecule. These lead to 
spontaneous changes in conformation that allow either the insertion of the intact reactive 
loop into the main b sheet, resulting in the formation of an inactive “latent” form, or the 
insertion of the loop of one molecule into the b sheet of the next, resulting in the formation 
of polymers. Polymerization occurs in AAT with the common Z variant and with mutations 
at the opening of the sheet, leading to emphysema and cirrhosis. Mutations at the same site 
in a neuron-specific serpin result in neurodegeneration and dementia (Carrell R.W. and 
Lomas D.A. 2002 ) with pre-existing β-sheet leading to pathological consequence. The 
tendency to undergo loop–sheet polymerization is not restricted to AAT as other serpins 
undergo the same transformation. In a rare form of familial encephalopathy where neuronal 
inclusion bodies (FENIB) form, it was found that inclusion body formation to be the result of 
a mutant neuroserpin which undergoes loop-sheet polymerization. Structural modeling of 
the neuroserpin mutants indicate that it may lead to the instability of -sheet structure, 
increasing its propensity to gain an extraneous strand. Robin and Carrell [10] have 
suggested that such -promiscuity may account not only for the pathologic properties of 
serpins, but also could explain the ‘pathologic property of -sheets in prion disorder that 
seems to be caused by the induced transition from -helix to -strand [11].  
3. AAT, a response to malignancy and inflammation 
AAT augments in the serum of gastrointestinal [15], prostate [16], brain [17] as well as 
biliary tract cancer [18] patients. Also reports indicate increased serum AAT in pancreatic 
adenocarcinoma [19], breast tumors [20], and esophageal cancer [21]. A significant 
correlation between serum AAT level and stage of cancer have also been proposed [22, 23]. 
Several means by which AAT plays role in malignancy and inflammations have been 
proposed so far as described in the following paragraphs:  
a. Equilibrium hypothesis; it is assumed that changes in the ratio of a particular protease 
to its cognate inhibitor account for the increased potential of tumor formation [23]. 
Neutrophil elastase and AAT constitute a pair including protease and protease inhibitor 
counterpart which are in equilibration. Perturbation of this equilibration causes tissue 
damage and provides a favorable environment for carcinogenesis and tumor 
progression. Laboratory and clinical findings have indicated that deficiency in AAT is 
associated with the increased risk of cancers such as liver, bladder, gall bladder, 
malignant lymphoma, and lung cancer. Conversely elevated concentration of 
neutrophil elastase may promote development; invasion and metastasis of many types 
of cancers as a result of tissue damage and air trap which foster longer exposure to the 
carcinogens and hence promotion of cancer by degradation of extracellular matrix. In 
this regard tumor-necrosis-factor signaling pathway plays a role [24]. 
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b. The other hypothesis suggests the roles that are played by a protease inhibitor per se. 
While imbalanced equilibration between protease to its cognate inhibitor would affect 
malignancy (as described above), however the inhibitor by itself seems to play more 
complicated function. The finding of a high serum concentrations of protease inhibitor 
even in the advanced stage of cancer at first glance was paradoxical, since inhibitors 
such as AAT are supposed to counteract the destructive activity of proteolytic enzymes 
(e.g. trypsin). However, it became clear that the role of protease inhibitors is rather 
complex and that, in most types of cancers, they play important role in modulating the 
dynamics of the proteolysis, in which proteases, inhibitors, regulators, cytokines and 
growth factors interact with each other through unknown mechanisms that have yet to 
be explored [25]. Tissue dependency of protease inhibitor activity is another 
phenomenon observed in malignancies. Cancers originated from several tissues often 
produce tumor associated trypsin inhibitor (TATI), however the strongest expression of 
which could be seen in mucinous ovarian tumors, both in benign and malignant type of 
tumors. Thus it appears that expression of TATI is regulated by different mechanisms in 
different tissues. In the other word expression of TATI is tissue dependent. TATI is a 6 
kDa peptide, which is synthesized by several tumors and cell lines and produced by the 
mucosa of the gastrointestinal tract, where it is thought to protect the mucosal cells 
from proteolysis. Elevated serum and urine level of TATI occurs in connection with 
many types of cancer, especially mucinous ovarian cancer, pancreatitis, severe 
infections and tissue destruction. Thus TATI may behave as an acute phase reactant. 
While elevation of TATI in cancer and pancreatic disease is associated with expression 
of trypsin, but such a relationship has not been observed for the inflammatory disease. 
TATI inhibits trypsin-mediated degradation of extracellular matrix by tumor cells. 
Therefore it might control activation of tumor-associated trypsinogen [26].  
Regarding malignant diseases; increased level of TATI has been observed both in serum and 
urine. In most cancers the increased secretion is caused by tumors, however in acute-phase 
reaction which is induced by tissue destruction and advanced disease TATI secretion is 
associated with cancer invasion. The concentration of TATI in serum and urine correlates 
strongly with tumor invasion. Howeve there is more variation in urine concentrations of 
TATI; therefore the serum concentration of TATI is preferred if it is going to be used as an 
indicator of the degree of invasion [27].  
3.1 AAT as an acute phase response 
AAT is secreted into circulation and increased level of which is the result of at least three 
mechanisms: production by tumors, leakage from a diseased pancreas and as a reaction 
against tissue damage and by impaired renal function [28]. For supporting this proposal, 
Solakidi, et al, have shown that elevated serum tumor associated trypsin inhibitor (TATI) 
could be due to production of TATI by tumors [28]. They reached to this conclusion because 
none of patients had any signs or previous history of pancreatic disorders or impaired renal 
function. Moreover gastric and colorectal neoplasms of patients under study were positive 
for TATI immunoexpression which could explain the elevated TATI in serum as a result of 
tumor secretion. To find whether elevation of TATI could be explained in terms of acute-
phase reaction, measurement of TATI and CRP (C-reactive protein), a prototype of acute-
phase reactant proteins was done; the result of which indicated statistically significant 
correlation between serum TATI and acute-phase reactant protein level. This finding has 
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indicated regulation of TATI synthesis as an acute-phase reaction. In supporting this notion, 
Peracaula, et al, [29] have suggested that acute-phase proteins might play important role as 
sensor of diseases. Both level of acute-phase protein and glycosylation have reported to be 
altered in the inflammation and other diseases including cancer. Factors that promote acute-
phase protein synthesis and enhance the expression of specific glycosyltransferases, such as 
sialyltransferases and fucosyltransferases, may be up-regulated in some tumors which could 
explain the changes in acute-phase proteins level and specific N-glycosylation modifications 
of some acute-phase proteins in cancer.  
4. AAT as a tumor marker and its clinical applicability  
Elevation of serum AAT, assessment and association of its phenotype and genotype with 
regard to specific type of cancer has been subject of many studies on different types of 
cancers such as gastrointestinal cancers, brain tumors, biliary tract cancer, pancreatic 
adenocarcinoma, cancers of the prostate, breast, lung and liver [22, 23, 30-32]. Regarding 
esophageal cancer, there are limited reports available from Japan and Korea as well as our 
recent repot [21, 33]. These reports have suggested that serum AAT level could be 
considered as tumor marker. Our results show that the mean range of trypsin inhibitor 
capacity (TIC) and AAT level are significantly higher in patients than in healthy controls 
[34]. Hong and colleagues have observed significant increase in serum AAT in malignant 
esophageal cancer patients compared to benign tumors and healthy controls [35].  
Recently Hsu and colleagues identified AAT as a potential biomarker of gastric cancer in 
gastric juice. They showed gastric juice AAT concentration is markedly higher in gastric cancer 
patients than in healthy subjects, gastric ulcer patients, and duodenal ulcer patients [2]. 
Investigating the histological pattern and tumor location of patients, Schena and colleagues 
[36] showed that AAT represents a diagnostic index of neoplastic diseases, highly sensitive 
but less specific. Saito and colleagues [37] have investigated severe septic complications as 
the major cause of post-surgery mortality in esophageal cancer patients. They assessed acute 
phase proteins in the infection related complications post-surgery in a large number of 
patients with esophageal cancer and have compared this group of patients with a group of 
gastric cancer patients and the healthy controls. Elevation of AAT, alpha-1 acidglycoprotein, 
haptoglobin, and ceruloplasmin was more prominent in patients with esophageal cancer. 
Stenman and colleagues [27] showed that the TATI level increased in serum of patients with 
pancreatic, gastric, hepatocellular, biliary tract, and colorectal cancer. They concluded that 
TATI is a sensitive marker. It increased in 75–95% of pancreatic patients, 40–65% of gastric 
patients, 60–80% of hepatocellular patients, 75–100% of those with biliary tract, and 34–74% 
of patients with colorectal cancers [27].  
An outstanding study carried out by Varela, and López Sáez [38] indicates that plasma level 
of A1AP (alpha-1 antiprotease); a member of serpins superfamily increases in clinically 
active cancer compared to the normal controls and normal range values for clinically 
defined complete remission. The mean value of A1AP was lower in healthy individuals than 
individuals with chronic non-malignant diseases. Notably A1AP in both groups was lower 
than individuals with malignant tumors. They also defined a correlation between plasma 
A1AP level and the type of malignancy such that increased plasma A1AP follows the 
following scheme; breast, gastrointestinal, head and neck, and lung cancers. Also the mean 
www.intechopen.com
Structural Features, Biological  
Functions of the Alpha-1 Antitrypsin and Contribution to Esophageal Cancer 
 
287 
range of A1AP has shown to increase in the following clinical order: complete remission, 
local disease, local-regional disease and metastatic disease. Thus it was concluded that 
A1AP could be considered as a cancer marker that discriminates cancer from chronic non-
tumoral diseases as well as complete clinical remission from relapses[38]. Furthermore 
Solakidi and colleagues [28] have assessed level of tumor associated trypsin inhibitor (TATI) as 
well as the carcinoembryonic antigen (CEA), C-reactive protein (CRP), and AAT in association 
with malignancy or inflammation to demonstrate the role of TATI in gastric and colorectal 
cancers. Their results showed elevated level of TATI in 50% of patients with gastric cancer and 
in 41.7% of colorectal cancer patients. Interestingly, elevated level of TATI was observed in 
only 8% of patients with benign gastrointestinal malignancies. Thus, TATI can be used as a 
complementary tumor marker in addition to CEA for gastrointestinal cancers. This finding 
supports our [34] and other reports that elevation of protease inhibitors was observed in the 
advanced tumor stages. Whether such elevated protease inhibitors, such as TATI and AAT, 
are functionally effective in the inhibition of proteases or not could be the subject of further 
investigations. Summarizing our [34] and other reports, it could be concluded that AAT plays 
role as a biomarker for malignancies including esophageal cancer. 
5. AAT and esophageal cancer  
Esophageal cancer ranks among the top 10 most frequent cancers, characterized by poor 
prognosis and 5-years survival rate less than 10%. Despite many efforts and investigations, the 
mechanism underlying development of esophageal cancer is not well understood [39]. Iran is 
located in the so-called Asian esophageal cancer belt where reports indicate the highest 
incidence rate of squamous cell carcinoma of esophagus (SCCE) of the world from certain 
parts of this country. Although recent reports [40-43] indicate attempts for identifying the 
molecular etiology of SCCE in addition to achievement of suitable tumor markers for this 
cancer, such efforts have so far been unconvincing and further efforts are therefore required 
[34]. Delayed diagnosis is a major problem associated with SCCE that most often results in 
diagnosis of the disease in the advanced stages of tumorigenesis. In addition, the high invasive 
phenotype of SCCE together with metastatic potential leads to low curative resection and high 
frequency of relapses. For developing effective approaches of diagnosis, treatment, and follow-
up of SCCE availability of appropriate molecular markers is an asset. In this regard assessing 
proteases and their inhibitors such as AAT level could be helpful [21, 36, 37].  
In a recent study, we investigated the level of AAT in serum of SCCE patients, its trypsin 
inhibitory capacity (TIC), and association of its phenotype with genotype [21, 36, 37]. AAT 
deficiency is an inherited disease as it is characterized by the reduced level of AAT in the 
serum. The two common genotypes of AAT deficiency are type Z (PiZ) and type S (PiS), 
which are associated with several malignancies. We assessed the AAT phenotype as well as 
genotypes Z and S in SCCE and their association with malignancy in Azeri patients. 
Azerbaijan is a region in the north west of Iran composed of at least three provinces where 
epidemiological studies have indicated a high rate of esophageal cancer from this region in 
addition to the north eastern region of the country where the highest incidence rate of 
esophageal cancer in the world has reported from there. AAT phenotype identification was 
done using isoelectric focusing (IEF) and its genotype was determined by restriction fragment 
length polymorphism (RFLP). Results indicate that the mean range of trypsin inhibitory 
capacity (TIC) and AAT nephlometry are significantly different in patients than that of healthy 
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controls. Measurement of AAT indicated higher level of AAT in patients’ serum that was in 
accordance to what previously reported with regard to patho-physiological status and 
malignancies (as described in detail above). However, and as a significant finding we found 
that the augmented AAT is non-functional which accounts for further dysfunction as well as 
reduction of AAT proper protease inhibitor activity in SCCE patients. Moreover, 97.3% of 
SCCE patients were homozygote for MM (PiMM) (normal genotype), and only 2.7% were MS 
heterozygous. Neither of the PiZ and PiS genotypes were identified in the patients (P<0.05). 
Thus AAT is among those tumor suppressors whose augmentation doesn’t correlate with 
proper function, though it might be dysfunctional in tumors.  
Finding a cogent relationship between stages of SCCE at the time of diagnosis and change in 
marker serum level is important since it affects survival rate following to surgery as well as 
helping in choosing proper method of treatment. Assessing the pathology records of 
patients, we found that most diagnosis were done in the late stages of tumorigenesis when 
tumors were fully grown and developed into highly invasive and metastatic phenotype. 
This was unfortunately a shortcoming in some studies [21, 36, 37]. Due to nature of SCCE, 
disease related complications appear late. As a result, diagnosis by clinical examinations 
becomes only possible in the advanced stages of tumor development. This has been true for 
70.3% of cases in our study. Thus low rates of curative resection and high frequency of 
relapses was observed post-surgery (67.56% of mortality). This finding is in accordance with 
Yunping and colleagues[39] who found poor prognosis of esophageal cancer with an overall 
5 years survival rate less than 10% [39]. Thus measurement of AAT in the late stages of 
SCCE raises further challenges for the applicability of which as a tumor marker in order to 
be applied for early stage diagnosis. We propose that further studies are required regarding 
to the change in the level of AAT as a marker along with analysis its defective functionality 
in a large sample size to achieve a definite correlation between serum AAT, tumorigenesis, 
and stages of tumors. Further study is also required to establish a rational relationship 
between increased level of ATT as a response to defect in its function or as a response to 
malignancy and inflammation as suggested by other researchers (above) at cellular and 
molecular level. It should also be kept in mind that most SCCE are diagnosed in the late 
stages of tumorigenesis due to late referral of patients to clinics. Thus determining 
augmented AAT level in the early stages remains to be investigated in future studies. One 
way for elucidation AAT level in early stages of malignancies would be establishing definite 
relationship between inflammatory diseases and cancers, though the level of AAT increases 
in inflammation. In addition most malignancies exhibit increased production of 
inflammatory cytokines. This is also true for SCCE in which increased cyclooxigenase has 
been well documented [2, 5, 15, 21, 22, 34, 36, 37, 44].  
6. Conclusion 
The poor prognosis of malignancies including SCCE in addition to late diagnosis in the 
advanced stages of tumorigenesis for most cancers demand further efforts for achieving 
specific and appropriate tumor markers for early stage cancer detection. While we did not 
have access to the patients at the early stage of SCCE, combining our results with other 
investigations indicate that AAT is a suitable prognostic rather than early stage diagnostic 
tumor marker as both we and others found its correlation with the advanced stages of 
tumors. As a tumor marker, AAT is highly sensitive, however, like most other tumor 
markers; it lacks tissue specificity which in fact is a drawback for its organ or tissue specific 
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applicability. Increasing the size of the population under study, establishing a rational 
correlation between malignancies and inflammatory diseases as well as combining AAT 
with other tumor markers might be helpful for achieving a better picture of AAT 
applicability for early stage SCCE and other tumors detection as well as specificity for 
prediction and evaluation of curative treatment.  
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